DK3344614T5 - Terapeutiske forbindelser til smerte og syntese deraf - Google Patents

Terapeutiske forbindelser til smerte og syntese deraf Download PDF

Info

Publication number
DK3344614T5
DK3344614T5 DK16842971.0T DK16842971T DK3344614T5 DK 3344614 T5 DK3344614 T5 DK 3344614T5 DK 16842971 T DK16842971 T DK 16842971T DK 3344614 T5 DK3344614 T5 DK 3344614T5
Authority
DK
Denmark
Prior art keywords
pain
synthesis
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
DK16842971.0T
Other languages
English (en)
Other versions
DK3344614T3 (da
Inventor
Bart Lieven Daniel Decorte
Jacob Cornelis Russcher
Menno Cornelis Franciscus Monnee
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of DK3344614T3 publication Critical patent/DK3344614T3/da
Application granted granted Critical
Publication of DK3344614T5 publication Critical patent/DK3344614T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK16842971.0T 2015-09-04 2016-09-01 Terapeutiske forbindelser til smerte og syntese deraf DK3344614T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214727P 2015-09-04 2015-09-04
US201562214734P 2015-09-04 2015-09-04
PCT/US2016/049871 WO2017040764A1 (en) 2015-09-04 2016-09-01 Therapeutic compounds for pain and synthesis thereof

Publications (2)

Publication Number Publication Date
DK3344614T3 DK3344614T3 (da) 2020-07-27
DK3344614T5 true DK3344614T5 (da) 2021-08-30

Family

ID=58188341

Family Applications (4)

Application Number Title Priority Date Filing Date
DK16842973.6T DK3344626T5 (da) 2015-09-04 2016-09-01 Terapeutiske forbindelser til smerte og syntese deraf
DK16842976.9T DK3344628T5 (da) 2015-09-04 2016-09-01 Terapeutiske forbindelser og syntese
DK16842971.0T DK3344614T5 (da) 2015-09-04 2016-09-01 Terapeutiske forbindelser til smerte og syntese deraf
DK16842975.1T DK3344627T5 (da) 2015-09-04 2016-09-01 Terapeutiske forbindelser til smerte og syntese deraf

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK16842973.6T DK3344626T5 (da) 2015-09-04 2016-09-01 Terapeutiske forbindelser til smerte og syntese deraf
DK16842976.9T DK3344628T5 (da) 2015-09-04 2016-09-01 Terapeutiske forbindelser og syntese

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16842975.1T DK3344627T5 (da) 2015-09-04 2016-09-01 Terapeutiske forbindelser til smerte og syntese deraf

Country Status (11)

Country Link
US (9) US9994572B2 (da)
EP (5) EP3344628B9 (da)
JP (5) JP6639651B2 (da)
CN (5) CN108495854B (da)
CA (5) CA2997545C (da)
DK (4) DK3344626T5 (da)
ES (4) ES2809703T3 (da)
IL (5) IL257740A (da)
MA (1) MA45011A (da)
TW (11) TWI683815B (da)
WO (5) WO2017040772A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997545C (en) * 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469781A (en) 1974-06-10 1977-04-06 Boehringer Sohn Ingelheim Production of scopine
US4232026A (en) * 1978-07-20 1980-11-04 Merck & Co., Inc. Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
JPH06502303A (ja) 1990-10-05 1994-03-17 バーネス，ウェーン・エム 熱安定性ｄｎａポリメラーゼ
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE602004021921D1 (de) * 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
DK1678172T3 (da) * 2003-10-15 2010-04-06 Targacept Inc Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
KR20080035649A (ko) * 2005-08-22 2008-04-23 타가셉트 인코포레이티드 헤테로아릴로 치환된 디아자트리시클로알칸, 그 제조방법및 용도
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008104955A1 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
WO2009124755A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh) 2010-01-04 2013-05-29 南昌弘益科技有限公司 噻托溴铵无水物及其制备方法
CN102579458A (zh) * 2012-03-08 2012-07-18 冀中能源峰峰集团有限公司总医院 缓解静点药物所致疼痛和防治静脉炎的药品配方
JP6102122B2 (ja) * 2012-08-24 2017-03-29 ソニー株式会社 画像処理装置および方法、並びにプログラム
ES2602039T3 (es) * 2012-09-18 2017-02-17 Heptares Therapeutics Limited Compuestos aza bicíclicos como agonistas del receptor M1 muscarínico
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI627174B (zh) * 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
CA2997545C (en) * 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Also Published As

Publication number Publication date
JP6736659B2 (ja) 2020-08-05
TW201920176A (zh) 2019-06-01
TWI639597B (zh) 2018-11-01
IL257734B (en) 2021-07-29
US20180291024A1 (en) 2018-10-11
TWI686393B (zh) 2020-03-01
TWI663167B (zh) 2019-06-21
US10040796B2 (en) 2018-08-07
EP3344628A4 (en) 2019-03-27
ES2807901T3 (es) 2021-02-24
CN109071540B (zh) 2021-06-04
US9994572B2 (en) 2018-06-12
TWI683815B (zh) 2020-02-01
TW201835082A (zh) 2018-10-01
TW201722955A (zh) 2017-07-01
DK3344627T3 (da) 2020-07-20
EP3344626A4 (en) 2019-03-27
TWI654188B (zh) 2019-03-21
EP3344626A1 (en) 2018-07-11
ES2812233T9 (es) 2022-02-18
MA45011A (fr) 2021-06-02
EP3344626B1 (en) 2020-07-08
JP2018526388A (ja) 2018-09-13
CA2997541A1 (en) 2017-03-09
ES2809703T3 (es) 2021-03-05
EP3344627A4 (en) 2019-03-27
CA2997501A1 (en) 2017-03-09
IL257732A (en) 2018-04-30
WO2017040778A1 (en) 2017-03-09
CA2997543C (en) 2022-07-19
TW201722951A (zh) 2017-07-01
US20180327405A1 (en) 2018-11-15
IL257735B (en) 2022-01-01
US10766898B2 (en) 2020-09-08
EP3344628A1 (en) 2018-07-11
CA2997430A1 (en) 2017-03-09
JP2018527356A (ja) 2018-09-20
EP3344614A4 (en) 2019-03-27
DK3344626T3 (da) 2020-07-27
CN108495854A (zh) 2018-09-04
ES2808048T9 (es) 2022-02-01
EP3344626B9 (en) 2021-08-11
JP2018527355A (ja) 2018-09-20
EP3344629A1 (en) 2018-07-11
US10040797B2 (en) 2018-08-07
TW201843153A (zh) 2018-12-16
IL257737A (en) 2018-04-30
TW201811786A (zh) 2018-04-01
TW201722953A (zh) 2017-07-01
WO2017040767A1 (en) 2017-03-09
EP3344614A1 (en) 2018-07-11
TW201722954A (zh) 2017-07-01
JP2018531907A (ja) 2018-11-01
DK3344614T3 (da) 2020-07-27
IL257732B (en) 2020-11-30
WO2017040772A9 (en) 2019-03-07
DK3344626T5 (da) 2021-09-06
WO2017040764A1 (en) 2017-03-09
CN108349934B (zh) 2021-10-22
TW201716409A (zh) 2017-05-16
DK3344628T5 (da) 2021-07-26
CA2997541C (en) 2022-01-11
JP6868008B2 (ja) 2021-05-12
IL257737B (en) 2022-10-01
US10040795B2 (en) 2018-08-07
JP6639651B2 (ja) 2020-02-05
TWI641608B (zh) 2018-11-21
CN109153679A (zh) 2019-01-04
US20170066769A1 (en) 2017-03-09
TW201833110A (zh) 2018-09-16
EP3344628B1 (en) 2020-07-15
US10351565B2 (en) 2019-07-16
ES2809703T9 (es) 2022-01-24
DK3344627T5 (da) 2021-08-30
US20180327406A1 (en) 2018-11-15
JP2018526387A (ja) 2018-09-13
EP3344614B9 (en) 2021-07-28
TWI707854B (zh) 2020-10-21
TWI672303B (zh) 2019-09-21
DK3344628T3 (da) 2020-08-03
EP3344628B9 (en) 2021-06-30
CN108290890B (zh) 2021-08-06
ES2807901T9 (es) 2022-01-31
US20170066767A1 (en) 2017-03-09
CN109071540A (zh) 2018-12-21
IL257734A (en) 2018-04-30
US10155762B2 (en) 2018-12-18
TWI713879B (zh) 2020-12-21
EP3344629A4 (en) 2019-03-27
CA2997545C (en) 2022-01-11
TWI695836B (zh) 2020-06-11
WO2017040770A1 (en) 2017-03-09
CN109153679B (zh) 2022-04-08
CN108349934A (zh) 2018-07-31
US20170066760A1 (en) 2017-03-09
US10358448B2 (en) 2019-07-23
ES2808048T3 (es) 2021-02-25
CA2997545A1 (en) 2017-03-09
CA2997543A1 (en) 2017-03-09
IL257735A (en) 2018-04-30
TWI636054B (zh) 2018-09-21
WO2017040772A1 (en) 2017-03-09
IL257737B2 (en) 2023-02-01
CN108290890A (zh) 2018-07-17
ES2812233T3 (es) 2021-03-16
JP6736661B2 (ja) 2020-08-05
TW201819381A (zh) 2018-06-01
JP6736660B2 (ja) 2020-08-05
US10351566B2 (en) 2019-07-16
CA2997501C (en) 2022-05-10
US20170066768A1 (en) 2017-03-09
EP3344627A1 (en) 2018-07-11
EP3344627B1 (en) 2020-07-01
CN108495854B (zh) 2021-10-15
EP3344627B9 (en) 2021-08-04
EP3344614B1 (en) 2020-07-08
US20170066770A1 (en) 2017-03-09
IL257740A (en) 2018-04-30
US20190112311A1 (en) 2019-04-18
CA2997430C (en) 2021-05-11

Similar Documents

Publication Publication Date Title
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
DK3294770T3 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3328880T3 (da) Terapeutiske midler
DK3250237T3 (da) Hemiasterlinderivater til konjugering og terapi
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3200615T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3183260T3 (da) Modificerede oligonukleotider og fremgangsmåder til deres syntese
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3452475T3 (da) Tetrahydropyridodiazepinforbindelser til at behandle smerte og smerterelaterede tilstande
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
DK3129057T3 (da) Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi
DK3431460T3 (da) Ny formulering og fremgangsmåde til syntese
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
DK3190116T3 (da) Pyrazolothiazolforbindelse og medicin omfattende denne
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf
DK3288965T3 (da) Opløselig kimær interleukin-10 receptor og terapeutisk anvendelse deraf